Toggle Main Menu Toggle Search

Open Access padlockePrints

Low-dose dexamethasone as a treatment for women with heavy menstrual bleeding: Protocol for response-adaptive randomised placebo-controlled dosefinding parallel group trial (DexFEM)

Lookup NU author(s): Professor Brian Walker

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2015, BMJ Publishing Group. All rights reserved.Introduction: Heavy menstrual bleeding (HMB) diminishes individual quality-of-life and poses substantial societal burden. In HMB endometrium, inactivation of cortisol (by enzyme 11β hydroxysteroid dehydrogenase type 2 (11βHSD2)), may cause local endometrial glucocorticoid deficiency and hence increased angiogenesis and impaired vasoconstriction. We propose that 'rescue' of luteal phase endometrial glucocorticoid deficiency could reduce menstrual bleeding. Methods and analysis: DexFEM is a double-blind response-adaptive parallel-group placebo-controlled trial in women with HMB (108 to be randomised), with active treatment the potent oral synthetic glucocorticoid dexamethasone, which is relatively resistant to 11βHSD2 inactivation. Participants will be aged over 18 years, with mean measured menstrual blood loss (MBL) for two screening cycles ≥50 mL. The primary outcome is reduction in MBL from screening. Secondary end points are questionnaire assessments of treatment effect and acceptability. Treatment will be for 5 days in the mid-luteal phases of three treatment menstrual cycles. Six doses of low-dose dexamethasone (ranging from 0.2 to 0.9 mg twice daily) will be compared with placebo, to ascertain optimal dose, and whether this has advantage over placebo. Statistical efficiency is maximised by allowing randomisation probabilities to 'adapt' at five points during enrolment phase, based on the response data available so far, to favour doses expected to provide greatest additional information on the dose-response. Bayesian Normal Dynamic Linear Modelling, with baseline MBL included as covariate, will determine optimal dose (re reduction in MBL). Secondary end points will be analysed using generalised dynamic linear models. For each dose for all end points, a 95% credible interval will be calculated for effect versus placebo. Ethics and dissemination: Dexamethasone is widely used and hence well-characterised safety-wise. Ethical approval has been obtained from Scotland A Research Ethics Committee (12/SS/0147). Trial findings will be disseminated via open-access peer-reviewed publications, conferences, clinical networks, public lectures, and our websites. Trial registration number: ClinicalTrials.gov NCT01769820; EudractCT 2012-003405-98.


Publication metadata

Author(s): Warner P, Weir CJ, Hansen CH, Douglas A, Madhra M, Hillier SG, Saunders PTK, Iredale JP, Semple S, Walker BR, Critchley HOD

Publication type: Article

Publication status: Published

Journal: BMJ Open

Year: 2015

Volume: 5

Issue: 1

Print publication date: 01/01/2015

Online publication date: 14/01/2015

Acceptance date: 31/10/2014

Date deposited: 22/12/2017

ISSN (electronic): 2044-6055

Publisher: BMJ Publishing Group

URL: https://doi.org/10.1136/bmjopen-2014-006837

DOI: 10.1136/bmjopen-2014-006837

PubMed id: 25588784


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
MR/J003611/1

Share